Leveraging a global patent portfolio to maximize value can be a complicated challenge for pharmaceutical products marketed internationally.
A key concern for many companies is how best to optimize market exclusivity in different commercially relevant territories.
Understanding key differences in the patent term extension laws of the US, Europe and Japan is essential to knowing when a product is eligible for extension and where.
Please join us for a lively discussion that will address topics including:
- Important differences and similarities between patent term extension regimes in the United States, Europe and Japan (including when combination products and esters/salts are considered “new” enough to be eligible)
- Strategies for maximizing Patent Term Adjustment for United States patents
- Aligning patent prosecution strategies with regulatory approval and non-patent regulatory exclusivities (such as NCE exclusivity in the US and supplemental protection certificates (SPCs) in Europe).
- Thorsten Bausch, Ph.D. - Partner, Cehmical, Biotech & Pharmaceutical Group, Hoffmann Eitle
- Courtenay Brinckerhoff - Partner, Chemical, Biotech & Pharmaceutical Practice, Foley & Lardner LLP
- Harumi Kojo - Former IP Judge in the Tokyo High Court, Partner, Sakurazaka Law Offices
- Hisatoshi Shinagawa, Ph.D. - Partner, Aoyama & Partners
- Bianca-Lucia Vos, Ph.D. - European Patent Attorney, Chemical, Biotech & Pharmaceutical Group, Hoffmann Eitle
Due to seating limitations, pre-registration is required. To register, please use either the Register button above, or contact Delia Dai at ddai foley.com or 312.832.4506.